Osteopontin in the development of systemic sclerosis--relation to disease activity and organ manifestation
Open Access
- 20 July 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 49 (10) , 1989-1991
Abstract
Sir, SSc is characterized by an interplay between early immunological activation and vascular damage, resulting in the generation of activated fibrogenic fibroblasts and, ultimately, excessive synthesis of extracellular matrix with deposition of increased amounts of structurally normal collagen [1, 2]. The organ involvement in SSc ranges from skin-limited to multi-organ fibrosis. Depending on the degree of skin involvement, SSc is frequently categorized as lcSSc or dcSSc type.Keywords
This publication has 10 references indexed in Scilit:
- Osteopontin in the development of systemic sclerosis--relation to disease activity and organ manifestationRheumatology, 2010
- Osteopontin modulates angiotensin II–induced inflammation, oxidative stress, and fibrosis of the kidneyKidney International, 2009
- Treatment of collagen‐induced arthritis with an anti‐osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cellsArthritis & Rheumatism, 2008
- Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarringJournal of Experimental Medicine, 2008
- Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary FibrosisPLOS Medicine, 2005
- Osteopontin modulates angiotensin II- induced fibrosis in the intact murine heartJACC, 2004
- Recordings or summaries of consultations for people with cancer2003
- Osteopontin—a molecule for all seasonsQJM: An International Journal of Medicine, 2002
- Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapyThe Lancet, 1996
- The Aetiopathogenesis of Systemic Sclerosis: Thick Skin—Thin HypothesesJournal of the Royal College of Physicians of London, 1995